CTSO · Cytosorbents Corp
$5.32
+0.36 (+7.26%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“approximately $4.4 million in unrestricted cash and cash equivalents and $1.5 million of non-current restricted cash which may not be sufficient to fund the Company's operations beyond the next twelve months from the issuance of these condensed consolidated financial statements. These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$15.58M
Shares
3.14M
Volume · Oct 20
79.22K
Avg daily vol (30 sessions)
44.8K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.32
Open$4.88
Day$4.53–5.35
52W close$3.06–17.00
Avg vol 30d45K
Short int124K · 3.9% float · 12.0d
Short vol52%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 23, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$37.22M
Trailing 12 months
Net income (TTM)
−$18.21M
Trailing 12 months
Revenue growth YoY
+0.2%
Year over year
Operating margin
-34.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-59.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$12.83M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-6.5%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
3.9%
Latest settlement · 12.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. CTSO reported Q2 2026 revenue of $9.6M, 73% gross margin, 27% lower operating loss and operating cash burn down to $200,000, reiterating its H2 2026 cash-flow break-even target. Management also highlighted a 58% severe-bleeding risk reduction in the STAR-T per-protocol analysis, FDA pre-submission meetings scheduled for DrugSorb-ATR, and constructive FDA feedback on HemoDefend-BGA's clinical pathway.
Bullish
- + STAR-T per-protocol CABG analysis showed a statistically significant win ratio of 1.59 for severe bleeding and a 58% relative risk reduction for severe bleeding or >1L chest-tube loss.
- + Two FDA pre-submission meetings are scheduled this month for DrugSorb-ATR, with a new De Novo submission anticipated in early 2027 and a parallel DOAC submission being explored.
- + Distributor/strategic-partner sales grew 16% YoY and direct sales outside Germany grew 9% YoY, supported by PuriFi and HotSwap platform adoption.
Bearish
- − Total Q2 revenue of $9.6M was flat YoY, as Germany sales declined 24% following sales-force restructuring.
- − The STAR-T primary MITT efficacy endpoints did not achieve statistical significance and the original De Novo application was denied; an appeal was upheld.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−46%
below
Price vs 50-day avg
−6%
below
RSI (14)
59
neutral
MACD trend
Positive
52-week position
16%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
−56%
trailing
YTD return
−58%
this year
Relative strength
−64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $10 — 200d above 50d
Institutional flow
Distributing
4 of 51 funds reported for Sep 30 · net -9.9K sh shares
Insider flow
Accumulating
Net +$120.4K over 90 days · 0% sells
Short interest
Rising
3.94% of float · ▲ +2.7% MoM · 12.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
51 holders — mid 3-yr range
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
+49%
Y/Y
Gross margin
118%
contracting
EPS growth
+66%
Y/Y
Free cash flow
$-12.5M
Balance sheet
$10.4M
net debt
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
11.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 9, 2023
Product gross margins
· in the near term
75% – 80%
Guided vs delivered
· last 1 settled
Product revenue
Full year 2021
guided at least $39.3M
$43.17M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−46%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
16%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $10 — 200d above 50d
Institutional flow
Distributing
4 of 51 funds reported for Sep 30 · net -9.9K sh shares
Insider flow
Accumulating
Net +$120.4K over 90 days · 0% sells
Short interest
Rising
3.94% of float · ▲ +2.7% MoM · 12.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
51 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $5 · 16%
Range high $17
vs 200-day avg -46%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $1.6M | Q2 2026 | — |
| Adjusted EBITDA – non-GAAP measure non-GAAP | -$3.76M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA, a non-GAAP measure non-GAAP | -$1.65M | the three months ended June 30, 2026 filing | — |
| Adjusted net loss non-GAAP | $2.8M | Q2 2026 | — |
| Adjusted net loss – non-GAAP measure non-GAAP | -$6.19M | Six Months Ended June 30, 2026 | — |
| EBITDA – non-GAAP measure non-GAAP | -$7.12M | Six Months Ended June 30, 2026 | — |
| Operating cash burn | $200,000 | Q2 2026 | — |
| Operating cash burn (net change in cash, cash equivalents, and restricted cash, excluding financ | -$400K | the three months ended June 30, 2026 filing | — |
| Total cash burn | $0.4M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTSO
this stock
Cytosorbents Corp
|
$15.58M | — | +48.5% | — | 3.9% |
|
ABT
Abbott Laboratories
|
$179.20B | -18.2% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$118.67B | -1.5% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -13.4% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.02B | -52.2% | +12.5% | 18.4 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTSO | +53.8% | +0.0% | -55.7% | +36.4% | -58.4% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +54.9% | +0.6% | -63.8% | +35.6% | -71.2% |